Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC
Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC
About this item
Full title
Author / Creator
Publisher
England
Journal title
Language
English
Formats
Publication information
Publisher
England
More information
Scope and Contents
Contents
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line tre...
Alternative Titles
Full title
Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_733789615
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_733789615
Other Identifiers
E-ISSN
1759-4782
DOI
10.1038/nrclinonc.2009.173
